Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

Condition(s) studied

Investigational drug(s) / intervention(s)

ITNK cell therapy: Infusion of ITNK/CAR-ITNK cells

Study summary

T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.

Eligibility

Primary outcome measure(s)

• The safety and tolerance of the ITNK cell immunotherapy — 2 years
  A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the ITNK cells, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5. Incidence of treatment-emergent adverse events will be calculated as standard methods.

Trial sites (1)

More Second Affiliated Hospital of Guangzhou Medical University trials in China